Folate receptor 1 antibodies and immunoconjugates and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
1. A humanized antibody or antigen binding fragment thereof that specifically binds a human folate receptor 1, wherein the antibody or antigen binding fragment comprises:
(a) a heavy chain CDR1 comprising GYFMN (SEQ ID NO:1); a heavy chain CDR2 comprising RIHPYDGDTFYNQKFQG (SEQ ID NO: 2); and a heavy chain CDR3 comprising YDGSRAMDY (SEQ ID NO:3); and
(b) a light chain CDR1 comprising KASQSVSFAGTSLMH (SEQ ID NO:7); a light chain CDR2 comprising RASNLEA (SEQ ID NO:8); and a light chain CDR3 comprising QQSREYPYT (SEQ ID NO:9).
2. An immunoconjugate having the formula (A)-(L)-(C), wherein:
(A) comprises the antibody or antigen binding fragment of claim 1 ;
(L) comprises a linker; and
(C) comprises a cytotoxic agent,
wherein said linker (L) links (A) to (C).
3. The immunoconjugate of claim 2 , wherein (A) comprises an antibody comprising the heavy chain of SEQ ID NO:6 and the light chain of SEQ ID NO:12 or SEQ ID NO:13.
4. The immunoconjugate of claim 2 , wherein (A) comprises an antibody or antigen binding fragment encoded by the plasmid DNA deposited with the ATCC on Apr. 7, 2010 and having ATCC deposit nos. PTA-10772, PTA-10773, or 10774.
5. The immunoconjugate of claim 2 , wherein (A) comprises an antibody or antigen binding fragment that competes with chMov19 for specific binding to a human folate receptor 1.
6. The immunoconjugate of claim 2 , wherein (A) comprises an antibody comprising the heavy chain variable domain of SEQ ID NO:4, and the light chain variable domain of SEQ ID NO:10 or SEQ ID NO:11.
7. The immunoconjugate of claim 2 , wherein the antibody or antigen binding fragment, (A), binds to a human folate receptor 1 with a Kd of 10 nM or less.
8. The immunoconjugate of claim 2 , wherein (L) comprises a linker selected from the group consisting of N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP) or N-succinimidyl 4-(2-pyridyldithio)-2-sulfopentanoate (sulfo-SPP); N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) or N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB); N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC); N-sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N-succinimidyl-4-(iodoacetyl)-ammobenzoate (SIAB); and N-succinimidyl-[(N-maleimidopropionamido)-tetraethyleneglycol]ester (NHS-PEG 4 -maleimide).
9. The immunoconjugate of claim 2 , wherein (C) comprises a cytotoxic agent selected from the group consisting of a maytansinoid, benzodiazepine, taxoid, CC-1065, duocarmycin, calicheamicin, dolastatin, auristatin, tomaymycin, and leptomycin or a prodrug of the cytotoxic agent.
10. The immunoconjugate of claim 2 , wherein (C) comprises N(2′)-deacetyl-N(2)-(3-mercapto-1-oxopropyl)-maytansine or N(2′)-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine.
11. The immunoconjugate of claim 10 , wherein
(A) comprises a humanized antibody comprising a heavy chain variable domain of SEQ ID NO:4, and a light chain variable domain of SEQ ID NO:10 or SEQ ID NO:11;
(L) comprises N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB); and
(C) comprises N(2′)-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine.
12. A pharmaceutical composition comprising the immunoconjugate of claim 2 and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , wherein the immunoconjugates have an average of about 3 to about 4 (C) per (A).
14. A diagnostic reagent comprising the antibody or antigen binding fragment of claim 1 which is labeled.
15. A kit comprising the antibody or antigen binding fragment of claim 1 .
16. The humanized antibody or antigen binding fragment of claim 1 , wherein said antibody or antigen binding fragment comprises a heavy chain variable domain of SEQ ID NO:4 and a light chain variable domain of SEQ ID NO:10 or SEQ ID NO:11.
17. The humanized antibody or antigen binding fragment of claim 1 , wherein said antibody or antigen binding fragment comprises a heavy chain of SEQ ID NO:6 and a light chain of SEQ ID NO:12 or SEQ ID NO:13.
18. The immunoconjugate of claim 10 , wherein
(A) comprises a humanized antibody comprising a heavy chain variable domain of SEQ ID NO:4, and a light chain variable domain of SEQ ID NO:11;
(L) comprises N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB); and
(C) comprises N(2′)-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine.
19. A pharmaceutical composition comprising the immunoconjugate of claim 11 and a pharmaceutically acceptable carrier.
20. A pharmaceutical composition comprising the immunoconjugate of claim 18 and a pharmaceutically acceptable carrier.